Description |
1 online resource : illustrations (black and white, and colour) |
Series |
SAGE knowledge. Cases |
|
SAGE knowledge. Cases
|
Summary |
In September 2004, Merck announced a voluntary withdrawal of Vioxx, one of its top earning drugs, after a new study suggested that it increased the risk of heart attacks. In only a few days, Merck's share price collapsed, and nearly $25 billion in shareholder wealth was erased. This case examines the market reaction to Merck's product recall |
Notes |
Originally Published in: Hutchins, S. (2006). Lehman Brothers Research: An Analyst Decides that the Market Overreacted to Merck's Vioxx Woes. 06-014. New Haven, CT: Yale School of Management, Yale University |
|
Online resource; title from home page (viewed on May 3, 2016) |
Subject |
Merck & Co.
|
SUBJECT |
Merck & Co. fast |
Subject |
Investment analysis -- Case studies
|
|
Stocks -- Prices -- Case studies
|
|
Investment analysis
|
|
Stocks -- Prices
|
Genre/Form |
Case studies
|
|
Case studies.
|
|
Études de cas.
|
Form |
Electronic book
|
ISBN |
9781473974418 |
|
1473974410 |
|